DE69924262D1 - Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen - Google Patents

Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen

Info

Publication number
DE69924262D1
DE69924262D1 DE69924262T DE69924262T DE69924262D1 DE 69924262 D1 DE69924262 D1 DE 69924262D1 DE 69924262 T DE69924262 T DE 69924262T DE 69924262 T DE69924262 T DE 69924262T DE 69924262 D1 DE69924262 D1 DE 69924262D1
Authority
DE
Germany
Prior art keywords
proteins
production
kapsid
typs
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924262T
Other languages
English (en)
Other versions
DE69924262T3 (de
DE69924262T2 (de
Inventor
Tornese Buonamassa
E Greer
L Galeotti
Giuliano Bensi
Roberto Petracca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22258285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69924262(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE69924262D1 publication Critical patent/DE69924262D1/de
Publication of DE69924262T2 publication Critical patent/DE69924262T2/de
Publication of DE69924262T3 publication Critical patent/DE69924262T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE69924262T 1998-08-14 1999-08-13 Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen Expired - Lifetime DE69924262T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9662598P 1998-08-14 1998-08-14
US96625P 1998-08-14
PCT/US1999/018016 WO2000009699A2 (en) 1998-08-14 1999-08-13 Method for producing yeast expressed hpv types 6 and 16 capsid proteins

Publications (3)

Publication Number Publication Date
DE69924262D1 true DE69924262D1 (de) 2005-04-21
DE69924262T2 DE69924262T2 (de) 2006-01-26
DE69924262T3 DE69924262T3 (de) 2009-07-23

Family

ID=22258285

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924262T Expired - Lifetime DE69924262T3 (de) 1998-08-14 1999-08-13 Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen

Country Status (5)

Country Link
EP (1) EP1105495B2 (de)
AT (1) ATE291089T1 (de)
CA (1) CA2340422C (de)
DE (1) DE69924262T3 (de)
WO (1) WO2000009699A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CN101180312A (zh) 2005-02-18 2008-05-14 诺华疫苗和诊断公司 来自尿路病原性大肠杆菌的免疫原
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP1877087B1 (de) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402898B (de) * 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
CA2267639C (en) * 1996-10-04 2005-11-22 Merck & Co., Inc. Synthetic hpv16 virus-like particles

Also Published As

Publication number Publication date
DE69924262T3 (de) 2009-07-23
CA2340422A1 (en) 2000-02-24
DE69924262T2 (de) 2006-01-26
EP1105495A2 (de) 2001-06-13
EP1105495B2 (de) 2009-01-21
EP1105495B1 (de) 2005-03-16
WO2000009699A9 (en) 2000-07-27
ATE291089T1 (de) 2005-04-15
CA2340422C (en) 2010-03-16
WO2000009699A3 (en) 2000-05-18
WO2000009699A2 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
FR15C0079I2 (fr) Expression optimisee de hpv 31 l1 dans la levure
DE59402827D1 (de) Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
HUP9903829A1 (hu) RNS-vírusok fertőző klónjai,belőlük kifejlesztett vakcinák és diagnosztikai eljárások
AR039005A1 (es) Antigenos virales
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
DE69924262D1 (de) Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen
EP1687329B8 (de) Optimierte expression von hpv-58-l1 in hefe
MY148656A (en) Optimized expression of hpv 52 l1 in yeast.
FR11C0022I2 (fr) Production de proteine de capside de virus du papillome humain et particules de type viral
YU37502A (sh) Infektivni klonovi
ATE369428T1 (de) Behandlung von gebärmutterhalskrebs
WO1999061052A3 (en) Oral immunization with papillomavirus virus-like particles
RU97110164A (ru) Очищенные белки вируса папилломы
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
ATE345814T1 (de) Herstellung eines chimeren papillomavirus
WO2005090584A3 (de) Impfstoff gegen influenza basierend auf geflügelpestviren
DE59812566D1 (de) Verfahren zur gewinnung von virusähnlichen partikeln auf der basis von polyomaviren
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
JP2002509863A5 (de)
WO2002055542A3 (de) Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren
WO2000014112A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
Jin et al. Biofilm-forming ability of Candida albicans is unlikely to contribute to high oral yeast carriage in human immunodeficiency virus infection
WO1998001570A3 (en) Mutated antibody-dependent infection enhancing domains of hiv
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., EMERY, US